✦ LIBER ✦

Stable dry powder formulation for nasal delivery of anthrax vaccine

✍ Scribed by Wang, Sheena H. (author);Kirwan, Shaun M. (author);Abraham, Soman N. (author);Staats, Herman F. (author);Hickey, Anthony J. (author)

Publisher: John Wiley and Sons Inc.
Year: 2012
Tongue: English
Weight: 714 KB
Volume: 101
Category: Article
ISSN: 0022-3549
DOI: 10.1002/jps.22742

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Stable dry powder formulation for nasal

Stable dry powder formulation for nasal delivery of anthrax vaccine

✍ Wang, Sheena H. (author);Kirwan, Shaun M. (author);Abraham, Soman N. (author);St 📂 Article 📅 2012 🏛 John Wiley and Sons Inc. 🌐 English ⚖ 714 KB

Anthrax vaccine powder formulations for

Anthrax vaccine powder formulations for nasal mucosal delivery

✍ Ge Jiang; Sangeeta B. Joshi; Laura J. Peek; Duane T. Brandau; Juan Huang; Matthe 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB

Anthrax remains a serious threat worldwide as a bioterror agent. A second-generation anthrax vaccine currently under clinical evaluation consists of a recombinant Protective Antigen (rPA) of Bacillus anthracis. We have previously demonstrated that complete protection against inhalational anthrax can

Back to basics: The development of a sim

Back to basics: The development of a simple, homogenous, two-component dry-powder inhaler formulation for the delivery of budesonide using miscible vinyl polymers

✍ F. Buttini; P. Colombo; M.P.E. Wenger; P. Mesquida; C. Marriott; Stuart A. Jones 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB 👁 1 views

It was hypothesised that formulating a dry-powder inhaler (DPI) using a refined, smooth grade of lactose, without fines and a polymer coated drug microparticle should produce an homogeneous formulation in which aerosolisation behaviour could be modified. Hence, the aim of this study was to develop a